Immunome's 10-K confirms the varegacestat story is real. HR=0.16 in Phase 3 RINGSIDE — 84% reduction in disease progression, ORR 56% vs 9% placebo, no deaths. That's not incremental. The company claims it's the lowest hazard ratio ever reported in a pivotal desmoid trial, and the numbers support it. NDA submission is on track for Q2 2026, PDUFA approximately Q2-Q3 2027.

The problem isn't the data. The problem is who else knows.

What the 10-K Shows

Financials are clean. $653.5M cash against $190.9M FY2025 operating burn. No going concern. No debt. EY clean audit. Runway is 2.5-3 years without another raise. The December 2025 offering at $21.50/share — right after Phase 3 topline — was smart capital management: raise while the data is fresh. But it brought shares from 43.3M (end-2023) to 113.1M (end-2025). 161% dilution in two years. ATM still has $134M remaining. More is coming.

Revenue is zero. AbbVie collaboration terminated July 2025. The only revenue source is gone. IMNM is running entirely on equity until varegacestat launches — if it launches. At $190-250M/year forward burn (NDA prep plus 6 IND submissions in 2026 plus pre-commercial build), even $653M depletes.

The pipeline behind varegacestat is where it gets interesting. HC74, their proprietary TOP1 inhibitor payload, outperformed AstraZeneca's DXd (the current gold standard for ADCs) across 89 tumor cell lines in preclinical work. Lower P-gp efflux, higher bystander activity, active in models where T-DXd and irinotecan failed. Six programs use this payload. IM-1021 (ROR1 ADC) is in Phase 1 with objective responses in B-cell lymphoma at multiple dose levels. Three more ADCs have IND submissions planned for 2026. IM-3050 is a FAP-targeted lutetium-177 radioligand therapy — IND cleared but Phase 1 delayed by diagnostic radiotracer supply chain issues.

The Corroboration That Shifts the Picture

Two findings from cross-referencing competitive data meaningfully change the framing:

Ovarian toxicity flips from bear to potential bull. The trawl flagged 55.6% ovarian toxicity in premenopausal women as the #1 commercial risk. Turns out nirogacestat's FDA label shows 75%. The approved competitor is worse on the key safety metric in a disease that skews young and female. OGSIVEO still generated $172M in its first full year with that profile. This is a class effect, but varegacestat appears to have an advantage, not a disadvantage.

The market is bigger than incident patients suggest. OGSIVEO's $172M FY2024 revenue on ≈1,650 incident US patients/year implies the prevalence pool and/or pricing are larger than simple patient count math. Peak sales forecasted above $1B. The commercial opportunity for a best-in-class second entrant is real.

Factor Decomposition

Idio:  65.8%   BELOW 75% threshold
XBI:   33.7%   (beta = 1.59)
SPY:    2.1%
MTUM:  -1.7%

Backward alpha: +47.1% (contaminated by Phase 3 rally)
Forward alpha (edge-adjusted): 0%

IMNM is one-third a biotech sector bet. For every 1% XBI moves, IMNM moves 1.59%. A sector selloff of 20% hits IMNM roughly 32%.

The 47.1% backward alpha is the $5.15-to-$27.65 rally that already happened. It's in the rearview mirror.

Forward alpha using the consensus target of $35.54 (14 analysts, all Buy) works out to 38.7% annualized — but that's the street's number. We have no informational advantage on any factor driving this stock. Edge-adjusted forward alpha is zero.

Why There's No Trade Here

Coverage kills edge. 14 analysts, 100% Buy consensus, mean target $35.54 (+69%). $2.3B market cap. This is not our edge zone. Every catalyst — NDA acceptance, PDUFA, IM-1021 data — is being modeled by Evercore, Goldman, Guggenheim, and eleven others.

Varegacestat approval is base case. The stock trades at $21.04, essentially the December offering price of $21.50. Investors who participated in that raise had the Phase 3 data in hand. Current price = approval priced in.

HC74 is the only non-consensus angle — but unvalidated. If IM-1021 Phase 1 data in 2026 shows clinical superiority over Merck's zilovertamab vedotin (which has a 63% Grade 3+ TRAE rate and a patient death flagged at ASCO 2025), the platform re-rates. But HC74 faces real competition: Kelun/MediLink has a Roche partnership worth $570M near-term, Hengrui is in Phase 3 with next-gen TOP1 payloads. Chinese competitors are clinically ahead.

Second-to-market economics are tight. BMS royalties (high single-digit to low-teen percent of net sales) plus up to $192M in milestones compress margins on a rare disease drug. Even at 70% market penetration and $200K/year pricing, peak net revenue after royalties might be $200M. That's a fine drug. It's not a multibagger from $2.3B market cap.

The Setup That Would Change This

IMNM at $12-14 on a biotech sector selloff (beta 1.59 amplifies the hit) with IM-1021 data imminent. At that price, you're buying the HC74 platform optionality for free and getting varegacestat as the funded base case. That setup doesn't exist today.

The insider signal is inconclusive: CEO Siegall bought $1.25M and CTO Tsai bought $205K in December 2025 (post-Phase 3, alignment not prediction). Director Barchas sold $8.3M the same month.

ATM IV at 186% (214th percentile vs 52-week range) means options are prohibitively expensive. No cheap way to express a view even if you had one.

Predictions

Two predictions recorded for calibration — not as trade signals:

• 90% probability FDA accepts varegacestat NDA without Refuse to File by September 30, 2026. Phase 3 data quality plus validated regulatory path (nirogacestat approved 2023) makes RTF very unlikely.
• 82% probability FDA approves varegacestat by December 31, 2027. Slightly off 90% because FDA/HHS instability (DOGE/RFK staffing disruption) is a wildcard, plus manufacturing/CMC unknowns.

Evidence